Evonetix is developing a desktop platform that synthesizes gene-length DNA with high accuracy and scalability using a novel approach to DNA synthesis. This technology provides researchers with rapid access to precise genetic material, addressing the limitations of current gene synthesis methods that hinder innovation in healthcare and biotechnology.
Funding
$67.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current gene synthesis methods often lack the accuracy and scalability needed to meet the demands of researchers in healthcare and biotechnology. This limitation hinders innovation and slows down the development of new therapies and technologies. Access to high-quality, gene-length DNA remains a bottleneck for many labs.
Solution
Evonetix is developing a desktop platform for gene synthesis that aims to provide researchers with rapid access to precise genetic material. Their technology offers a novel approach to DNA synthesis, enabling the creation of gene-length DNA with improved accuracy and scalability. By placing a gene foundry in every lab, Evonetix seeks to accelerate innovation in fields such as personalized medicine, novel antibody therapeutics, and other areas of engineering biology. The platform is designed to overcome the limitations of existing gene synthesis methods, empowering scientists to realize the full potential of engineering biology.
Target Audience
The primary target audience includes researchers in healthcare, biotechnology, and synthetic biology who require accurate and scalable gene synthesis capabilities.
Features
- Desktop platform for on-site gene synthesis.
- Novel DNA synthesis approach for improved accuracy.
- Scalable technology to meet the demands of modern research.
- Rapid access to gene-length DNA.